Capstone Therapeutics to Hold Quarterly Operating Update Conference Call
08 August 2013 - 4:16AM
Capstone Therapeutics (OTCQB:CAPS); (the
"Company"), will hold a conference call and webcast on Wednesday,
August 14, 2013 at 4:30 pm EDT. The call may be accessed at
877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying
slides may be viewed by logging onto the Investors section of the
Company's website, www.capstonethx.com. A replay will be available
beginning August 14, 2013 at 7:30 pm EDT until midnight August 17,
2013 and may be accessed at 855-859-2056 (U.S.) or 404-537-3406
(outside U.S.) with conference ID 27383573.
About Capstone Therapeutics
Capstone Therapeutics is a biotechnology company committed to
developing a pipeline of novel therapeutic peptides aimed at
helping patients with under-served medical conditions. The
Company is focused on development and commercialization of two
product platforms: AZX100 and ApoE Mimetic Peptide Molecule AEM-28
and its analogs (through the LipimetiX Development, LLC, joint
venture).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new
class of compounds in the field of smooth muscle relaxation and
fibrosis. AZX100 has been evaluated for commercially
significant medical applications such as the prevention or
reduction of hypertrophic and keloid scarring and treatment of
pulmonary and peridural fibrosis.
Apolipoprotein E (Apo E) is a 299 amino acid protein that plays
an important role in lipoprotein metabolism. AEM-28 is a 28
amino acid mimetic of Apo E that contains a domain that anchors
into a lipoprotein surface while also providing the Apo E binding
domain that is removed by heparin sulfate receptors in the liver.
AEM-28 as an Apo E mimetic has the potential to restore the ability
of atherogenic lipoproteins to be cleared from the plasma,
completing the reverse cholesterol transport pathway, and thereby
reducing cardiovascular risk.
Capstone's corporate headquarters are in Tempe,
Arizona. For more information, please visit the Company's
website: www.capstonethx.com.
Statements in this press release or otherwise attributable to
Capstone regarding our business that are not historical facts are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from predicted
results. These risks include the factors discussed in our Form
10-K for the fiscal year ended December 31, 2012, and other
documents we file with the U.S. Securities and Exchange
Commission
Editor's Note: This press release is also available under
the Investors section of the Company's website at
www.capstonethx.com.
CONTACT: FOR FURTHER INFORMATION:
Investor Relations
(602) 286-5250
investorinquiries@capstonethx.com
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jul 2023 to Jul 2024